8,965 Shares in Gilead Sciences, Inc. $GILD Purchased by Midwest Trust Co

Midwest Trust Co acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 8,965 shares of the biopharmaceutical company’s stock, valued at approximately $994,000.

Several other large investors have also bought and sold shares of GILD. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after purchasing an additional 1,520,809 shares during the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences in the 1st quarter worth $620,415,000. Finally, Nordea Investment Management AB raised its stake in shares of Gilead Sciences by 39.8% in the second quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company’s stock worth $436,648,000 after purchasing an additional 1,126,886 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research analyst reports. Sanford C. Bernstein reiterated an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Wolfe Research lifted their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Citigroup increased their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $128.27.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the sale, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. This represents a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 71,500 shares of company stock valued at $8,336,040 over the last three months. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $122.56 on Wednesday. The stock has a market cap of $152.07 billion, a P/E ratio of 24.41, a P/E/G ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock’s fifty day moving average is $116.79 and its 200 day moving average is $112.48. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 earnings per share. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.